## Drug Approved to Slow Alzheimer’s Progression## Drug Approved to Slow Alzheimer’s Progression Source: CNN Location: Not specified The US Food and Drug Administration (FDA) has approved donanemab, a monoclonal antibody that slows the progression of early symptomatic Alzheimer’s disease. Developed by Eli Lilly, donanemab helps remove amyloid plaques from the brain, a hallmark of Alzheimer’s. It will be sold under the name Kisunla and cost $695 per vial, excluding insurance. A six-month course of treatment will cost approximately $12,522.
CNN
—
The U.S. Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
Donanemab, developed by Indianapolis-based Eli Lilly, helps the body clear amyloid plaques in the brain, a hallmark of Alzheimer’s disease.
Get the weekly newsletter from CNN Health
Lilly said the drug will be sold under the name Kisunla and will cost $695 per vial (excluding insurance). For a six-month course of treatment, that would work out to $12,522, or about $32,000 a year.
This is a developing story and will be updated.
